| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medicus Pharma Ltd.$0.31
+0.01 (+2.04%)
D 27Pipeline Score Overvalued Biotech · Clinical
Market Cap
17.00 M
EPS
-1.78
P/E Ratio
-
Value Trade
2.65 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.70 M
Operating CF
-8.97 M
Total Assets
7.43 M
Total Liabilities
6.00 M
Equity
1.33 M
-4.76 %
Week
-8.03 %
1 Month
-72.73 %
3 Month
-85.29 %
6 Month
-90.32 %
5 Year
-90.32 %
All Time
Cash Data
Cash Position
6.37 M
Monthly Burn
2.99 M
Runway
0 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
951.04 K
52 Week Range
0.25 - 7.73
% held by Insiders
12.97 %
% held by Institutions
17.55 %
Enterprise Value
14.33 M
Total Shares
56.63 M
Short %
27.62 %
Float Shares
49.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medicus Pharma Ltd.
217Total events
21Upcoming
60Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 2
TBD
T2Management Change
Subscribe to view catalyst details
TBD
T1Interim Analysis
Subscribe to view catalyst details
Event history 2
TBD
▲IND ClearanceTeverelix®FiledIND
Subscribe to view catalyst details
TBD
▲Trial InitiationSkinJect®ApprovedTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-26 | SkinJect™ (doxorubicin delivered through the SkinJect microneedle platform) | phase 2 data readout | Phase 2 | — | – | – | – |
2026-03-26 | SkinJect™ (doxorubicin delivered through the SkinJect microneedle platform) | phase 2 data readout | Phase 2 | — | – | – | – |
2026-03-26 | SkinJect™ (doxorubicin delivered through the SkinJect microneedle platform) | phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D27
Pipeline Score $4M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 30%
Micro Cap (rank 647 of 923)
Percentile RankMedicus Pharma Ltd. faces pipeline headwinds (27/100), with $1.2B risk-adjusted pipeline value, led by Teverelix DP in Advanced Prostate Cancer (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teverelix DP Small molecule | Advanced Prostate Cancer | Phase 2 | NCT07457164 | 10% | $643M | NOT YET_RECRUITING | 40 | VERY_FAST | F (15) | Dec 1, 2027 | - | Aug 1, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SkinJect® | basal cell carcinoma | Phase 2 | 2026-06-22 | 55% histological clearance and 64% clinical clearance | Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 Read More | |
SkinJect® | basal cell carcinoma | Phase 2 | 2026-06-22 | 55% histological clearance and 64% clinical clearance | Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 Read More | |
SkinJect® | basal cell carcinoma | Phase 2 | 2026-06-22 | 55% histological clearance and 64% clinical clearance | Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDCX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDCX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDCX▲ +9.4%on this news
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma Ltd. has appointed Dr. Faisal Mehmud as the new CEO of its UK subsidiary, Antev Limited, effective August 30, 2026. Dr. Mehmud, who also serves as Chief Medical Officer of Medicus, will lead Antev's efforts in advancing Teverelix® across various indications. His extensive experience in global pharmaceutical leadership is expected to enhance the company's strategic initiatives.
Read more →MDCXMedicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Medicus Pharma has received authorization from the UAE Department of Health to proceed with its PRECISION-E2 Phase 2a clinical study of Teverelix® in women suffering from moderate-to-severe endometriosis. This study aims to integrate genomic data with clinical outcomes to optimize treatment strategies. The IND approval marks a significant step in Medicus' commitment to advancing women's health therapies.
Read more →MDCX▼ -14%on this news· ran to -29% by day 3
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Medicus Pharma has received FDA authorization to initiate a Phase 2b clinical study for SkinJect® in patients with Gorlin Syndrome. This study aims to evaluate the efficacy and safety of the treatment, which delivers doxorubicin directly into basal cell carcinoma lesions. The FDA's recommendations have strengthened the study protocol, enhancing its scientific rigor.
Read more →MDCX▲ +16.5%on this news
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Medicus Pharma has received positive feedback from the FDA and central IRB approval for its optimized Phase 2 clinical study of Teverelix in men with acute urinary retention. The redesigned study will enroll approximately 126 patients, significantly less than the previously planned 390. The study aims to evaluate the pharmacodynamic effects of Teverelix on prostate volume and urinary function, potentially accelerating clinical development.
Read more →MDCXMedicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Medicus Pharma will present its clinical development strategies at the 2026 Bio International Conference. The focus will be on SkinJect®, a treatment for basal cell carcinoma, which has shown positive Phase 2 results. Updates on Teverelix®, a GnRH antagonist for various conditions, will also be discussed. The company is preparing for regulatory meetings and pursuing orphan drug designations.
Read more →MDCX▼ -5.2%on this news· ran to +35% by day 3
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted a request for Rare Pediatric Disease Designation for SkinJect®, a microneedle patch aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. The submission follows positive Phase 2 study results, indicating a 64% clinical clearance rate. The company aims to address the significant treatment burden faced by these patients with a non-surgical option.
Read more →MDCX▼ -5.2%on this news· ran to +35% by day 3shared move
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, a microneedle patch aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. This submission follows an earlier Orphan Drug Designation application and is supported by positive Phase 2 study results. The company aims to provide a non-surgical treatment option for this rare condition.
Read more →MDCXMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Medicus Pharma has initiated the PRECISION-E2 Phase 2a study to evaluate Teverelix® for treating symptomatic endometriosis in UAE women. This groundbreaking trial integrates genomic analyses from the Emirati Genome Program to explore treatment response variability. The study aims to personalize care and improve outcomes for women suffering from this chronic condition.
Read more →MDCXMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Medicus Pharma has announced the initiation of the PRECISION-E2 Phase 2a study to evaluate Teverelix® in women with symptomatic endometriosis. This innovative trial, leveraging the Emirati Genome Program, aims to explore treatment response variability through genomic analyses. The study is expected to provide insights that could transform endometriosis management and support future development in women's health indications.
Read more →MDCXMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Medicus Pharma has submitted a substantial modification application for Teverelix® aimed at advanced prostate cancer patients with high cardiovascular risk. This submission is a key step towards registrational development, addressing a significant unmet need in the treatment landscape. The planned Phase 2b study will optimize dosing and assess the drug's safety and efficacy profile. Medicus aims to initiate patient enrollment later this year, with the goal of establishing Teverelix® as a leading therapy in this area.
Read more →MDCXMedicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Medicus Pharma Ltd. has successfully submitted a substantial modification application for its Teverelix® program, focusing on patients with advanced prostate cancer who have elevated cardiovascular risk. This submission is an important step towards registrational development and aims to optimize dosage while characterizing the drug's pharmacokinetic and pharmacodynamic profiles. Teverelix® is positioned to provide significant advantages over traditional treatments, targeting a major unmet need in the oncology market. Medicus intends to initiate patient enrollment for the Phase 2b study later this year.
Read more →MDCX▲ +7%on this newsshared move
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
Medicus Pharma has submitted Protocol SKNJCT-005 to the FDA for SkinJect® in Gorlin Syndrome, a rare genetic disorder. This Phase 2b study aims to evaluate the efficacy and safety of SkinJect® as a potential lesion-directed therapy. If successful, it could become the first FDA-approved treatment for this condition, addressing a significant unmet medical need.
Read more →MDCX▲ +7%on this newsshared move
Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome
Medicus Pharma has announced the submission of Protocol SKNJCT-005 to the FDA for SkinJect, aimed at treating Gorlin Syndrome. This Phase 2b open-label study is intended to generate efficacy and safety data to support a future New Drug Application. The company aims to address the significant unmet need in Gorlin Syndrome, where current treatment options are limited. If successful, SkinJect could pioneer lesion-directed therapy for patients with this rare genetic condition.
Read more →MDCX▲ +6.7%on this news· ran to +23% by day 1
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Medicus Pharma Ltd. has announced a $22 million non-dilutive financing agreement with an institutional investor. The deal will bolster the company's cash position to around $30 million, providing a projected operating runway of over 24 months. The financing includes immediate capital and a structured release of additional funds based on milestone achievements.
Read more →MDCX▲ +5.3%on this news
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Medicus Pharma Ltd. has reported its financial results for Q1 2026, highlighting significant advancements in its clinical development programs, particularly for SkinJect® and Teverelix®. The company showcased positive outcomes from the Phase 2 SKNJCT-003 study for SkinJect® and received FDA clearance for a Phase 2b study of Teverelix®. However, the company also reported significant operating losses and ongoing financial concerns, although it has expanded its funding capabilities. Medicus aims to leverage its progress across multiple therapeutic areas throughout the year.
Read more →MDCX▲ +20.9%on this news
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
Medicus Pharma announced positive results from the expanded analysis of its Phase 2 SKNJCT-003 study, which evaluated the efficacy and safety of Doxorubicin Microneedle Array for treating nodular basal cell carcinoma. The analysis showed a clear dose-response relationship and reinforced the drug's therapeutic profile, paving the way for future discussions with the FDA. The findings suggest a shift in treatment approaches, potentially reducing the need for surgical interventions.
Read more →MDCX▼ -5.7%on this news
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Medicus Pharma's CEO, Dr. Raza Bokhari, met with key lawmakers to advocate for support on various healthcare initiatives, including Orphan Drug Designation for SkinJect® targeting Gorlin Syndrome. The discussions emphasized the urgent need for innovative treatments for patients suffering from this rare disease. Medicus aims to advance regulatory pathways for SkinJect® to provide non-surgical options for patients.
Read more →MDCX▼ -5.7%on this newsshared move
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Medicus Pharma's CEO, Dr. Raza Bokhari, met with lawmakers on Capitol Hill to advocate for critical healthcare initiatives, including Orphan Drug Designation for SkinJect® for Gorlin Syndrome. The discussions highlighted the urgent need for new treatment options for patients suffering from this rare disease. Medicus aims to advance regulatory pathways for SkinJect®, which offers a non-surgical approach to treatment.
Read more →MDCX▲ +17%on this news
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted an Orphan Drug Designation application for SkinJect® to the FDA, targeting basal cell carcinoma in Gorlin Syndrome patients. This rare genetic disorder leads to multiple skin cancers, and current treatments are limited. SkinJect® aims to provide a localized, non-surgical alternative, potentially improving patient outcomes.
Read more →MDCX▲ +17%on this newsshared move
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted an Orphan Drug Designation application to the FDA for SkinJect® aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. This submission highlights the company's strategy to address a significant unmet medical need, as current treatment options are limited and often involve invasive procedures. SkinJect® is designed to provide a localized, non-surgical treatment approach, potentially improving patient outcomes in this rare genetic disorder.
Read more →MDCX▼ -25%on this newsshared move
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
Medicus Pharma Ltd. announced the presentation of new Phase 1 clinical data on Teverelix, an investigational long-acting GnRH antagonist, at AACE 2026. The presentation will highlight predictable estradiol suppression and favorable safety profiles derived from studies with healthy premenopausal women. The findings support Teverelix's potential use across several hormone-driven conditions, particularly in women's health. The company is also exploring development collaborations aimed at optimizing clinical strategies for treating endometriosis.
Read more →MDCX▲ +9.8%on this news
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Medicus Pharma Ltd. has submitted an optimized Phase 2 study protocol for Teverelix, targeting the prevention of recurrent acute urinary retention in men with benign prostatic hyperplasia. The new study design, refined under the leadership of a prominent urology expert, aims to ensure a more efficient clinical development process and reduce overall costs. With no current approved therapies for this condition, Medicus is addressing a significant market need estimated at approximately $2 billion. The company anticipates a quicker path to commercialization via clear pharmacodynamic endpoints and interim analysis.
Read more →MDCX▼ -8.5%on this newsshared move
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Medicus Pharma Ltd. clarified the topline results from its Phase 2 study of SkinJect, a microneedle array for treating nodular basal cell carcinoma. The 200µg dose cohort demonstrated significant clinical activity, supporting further development. The company aims to focus on this dosage in upcoming regulatory discussions and potential partnerships.
Read more →MDCX▼ -9.6%on this newsshared move
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Medicus Pharma has reported positive Phase 2 results for its SkinJect therapy, achieving an 80% overall response rate in patients with nodular basal cell carcinoma. The independent validation by Dr. Babar Rao, a key opinion leader, supports the clinical significance of the data and suggests potential for non-surgical treatment options. The findings indicate a promising avenue for further development and regulatory discussions.
Read more →MDCX▼ -5.7%on this newsshared move
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
Medicus Pharma announced a business update call to discuss promising results from its Phase 2 SkinJect study, which reported an 80% overall response rate in the 200µg cohort. The call will feature insights from Dr. Babar Rao, highlighting the clinical significance of the findings and the potential to alleviate treatment backlogs for basal cell carcinoma. The company is also advancing plans for an AI-enabled clinical development platform.
Read more →MDCX▼ -5.7%on this newsshared move
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Medicus Pharma Ltd. reported its financial results for 2025, highlighting significant advancements in its clinical pipeline, particularly the completion of the Phase 2 SkinJect study. The company aims to expand into rare diseases and women's health, while also integrating AI-driven clinical development. Despite a strong capital position, concerns remain about ongoing operating losses and the company's future viability without additional financing.
Read more →MDCXMedicus Pharma To Discuss Positive Skinject® Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Medicus Pharma announced positive topline results from its Phase 2 study of SkinJect, showing a 73% clinical clearance rate in the 200-µg treatment arm. This suggests that approximately three out of four lesions treated may allow patients to avoid surgery. The company will discuss these findings in a fireside chat hosted by Brookline Capital Markets.
Read more →MDCXMedicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Medicus Pharma announced positive topline results from its Phase 2 SKNJCT-003 study, showing a 73% clinical clearance in patients treated with a 200-µg dose of SkinJect. This suggests that nearly three-quarters of treated lesions may allow patients to avoid surgery. The company will discuss these findings in a fireside chat on March 19, 2026.
Read more →MDCXMedicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
Medicus Pharma has appointed Dr. Babar K. Rao as the Principal Investigator for their Phase 2 SKNJCT-003 clinical trial, which evaluates the SkinJect platform for treating nodular basal cell carcinoma. The trial reported a significant 73% clinical clearance in patients, indicating the potential to avoid surgical interventions. The company will discuss these findings in an upcoming business update webcast, highlighting the significance of their clinical results and future development plans for the SkinJect program.
Read more →MDCXMedicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Medicus Pharma Ltd. will participate in the Longwood Miami CEO Forum from March 11-13, 2026. Dr. Raza Bokhari, the Executive Chairman & CEO, will discuss the company's AI-enabled drug development strategy aimed at improving clinical trial efficiency. The event will feature other notable industry leaders and is designed to foster discussions on advancing patient care.
Read more →MDCX▲ +34.3%on this newsshared move
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
Medicus Pharma has released positive results from its Phase 2 SKNJCT-003 study of SkinJect microneedle therapy for basal cell carcinoma. The treatment achieved 73% clinical clearance and 40% histological clearance in the 200-µg cohort, indicating significant efficacy. The company plans to use these results to advance discussions with the FDA and pursue strategic partnerships.
Read more →MDCX▲ +34.3%on this newsshared move
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
Medicus Pharma has reported positive results from its Phase 2 SKNJCT-003 study for SkinJect, a microneedle delivery system for treating basal cell carcinoma. The study showed a 73% clinical clearance rate in the 200-µg treatment cohort, indicating significant efficacy. The company plans to use these results to engage in regulatory discussions with the FDA and pursue strategic partnerships.
Read more →MDCX▼ -50.9%on this news· ran to -72% by day 1shared move
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
Medicus Pharma has reported positive topline results from its Phase 2 study SKNJCT-003, which evaluates the efficacy of Doxorubicin Microneedle Array for treating basal cell carcinoma. The 200µg cohort achieved 73% clinical clearance and 40% histological clearance by Day 57. The company plans to discuss these findings in an end of Phase 2 meeting with the FDA in 2026. However, the study was not designed for registrational endpoints, and regulatory approval remains uncertain.
Read more →MDCXMedicus Pharma To Participate in the 38th Annual Roth Conference
Medicus Pharma Ltd. will participate in the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, California. CEO Dr. Raza Bokhari will discuss the company's clinical development programs, particularly Skinject's potential for Gorlin Syndrome. The company aims to advance its drug development strategy and engage with investors during the event.
Read more →MDCXMedicus Pharma on Bloomberg World
Dr. Raza Bokhari, CEO of Medicus Pharma, discussed the company's strategies and the role of AI in drug development during a Bloomberg interview. He highlighted the company's significant investment in its pipeline and expressed optimism about upcoming Phase 2 clinical data readouts for Skinject. However, he acknowledged the volatility in biotech markets as a challenge.
Read more →MDCXMedicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Medicus Pharma has received FDA clearance to proceed with a Phase 2b study of Teverelix, a long-acting GnRH antagonist, in men with advanced prostate cancer and high cardiovascular risk. The study aims to optimize dosing and evaluate the drug's efficacy in achieving sustained testosterone suppression. Teverelix's unique mechanism may offer advantages over traditional therapies, particularly for patients with cardiovascular concerns.
Read more →MDCXMedicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Medicus Pharma has received FDA clearance to initiate a Phase 2b study of Teverelix, a long-acting GnRH antagonist, in men with advanced prostate cancer and high cardiovascular risk. The study aims to confirm medical castration and evaluate cardiovascular safety. Teverelix is designed to provide immediate receptor antagonism, potentially reducing cardiovascular risks associated with existing therapies.
Read more →MDCXMedicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
Medicus Pharma celebrated its one-year Nasdaq anniversary by ringing the Opening Bell. CEO Dr. Raza Bokhari highlighted the company's progress and focus on advancing its clinical pipeline, particularly SkinJect and Teverelix. The company is actively pursuing partnerships to enhance its development efforts. However, challenges remain, including unmet study endpoints and reduced royalty rates.
Read more →MDCXMedicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Medicus Pharma Ltd. has amended its license agreement with LifeArc, reducing the royalty rate on Teverelix from approximately 4% to 2%. This change is expected to enhance the long-term economic profile of Teverelix, which targets a market opportunity of around US$6 billion for treating acute urinary retention and prostate cancer. The amendment preserves global rights and intellectual property control, allowing for continued development and commercialization efforts.
Read more →MDCXMedicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Medicus Pharma Ltd. announced an amendment to its license agreement with LifeArc, reducing the royalty rate on Teverelix from approximately 4% to 2%. This change is expected to enhance the long-term economic profile of Teverelix, a drug aimed at treating Acute Urinary Retention and prostate cancer patients with cardiovascular risks. The amendment preserves global rights and intellectual property control while maintaining operational responsibilities.
Read more →MDCXMedicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
Medicus Pharma Ltd. will celebrate its first anniversary on Nasdaq with an Opening Bell ceremony on January 22, 2026. The company has focused on executing its clinical development programs, particularly for its SkinJect and Teverelix therapies. Medicus aims to partner with established pharmaceutical firms for late-stage development and commercialization of its assets.
Read more →MDCX▼ -5.8%on this news
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
Medicus Pharma Ltd. has announced that clinical data on its long-acting GnRH antagonist, Teverelix, have been accepted for presentation at the AACE Annual Meeting 2026. The Phase 1 studies involve 48 healthy premenopausal women, showing rapid hormone suppression and stable bone turnover markers. Teverelix is being explored for its applications in women's health, specifically targeting endometriosis, following promising results that support its further development. The company plans to advance to a Phase 2 study in UAE, as well as continue other projects, including its SkinJect™ program for basal cell carcinoma.
Read more →MDCXMedicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
Medicus Pharma Ltd. will present at Biotech Showcase 2026, highlighting its SkinJect Phase 2 program. The company aims to secure partnerships while advancing its clinical development. Positive interim results from the SkinJect study indicate over 60% clinical clearance. Medicus is also exploring regulatory pathways and AI collaborations to enhance its clinical strategies.
Read more →MDCX▼ -7.7%on this news
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Medicus Pharma Ltd. has announced a collaboration with Reliant AI to develop an AI-driven clinical data analytics platform aimed at enhancing the efficiency of clinical trials for its drug Teverelix. This partnership is expected to leverage advanced analytics to improve decision-making and trial execution. The initial phase will focus on dynamic site selection for a clinical study planned for 2026, with significant market potential in treating acute urinary retention and high cardiovascular risk prostate cancer.
Read more →MDCXMedicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. has completed the enrollment of 90 patients for its Phase 2 clinical study (SKNJCT-003) aimed at non-invasively treating basal cell carcinoma (BCC) using Doxorubicin Microneedle Array (D-MNA). The company anticipates releasing topline results in Q1 2026 and plans to request an end-of-phase 2 meeting with the FDA in H1 2026. The study has shown promising interim results, indicating a significant clinical clearance rate.
Read more →MDCXMedicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Medicus Pharma Ltd. has entered into a warrant inducement agreement, allowing for the immediate exercise of outstanding Series A and B Warrants. This agreement is expected to generate approximately $5.1 million in gross proceeds. The exercise price has been reduced to $1.92 per share, and new Series C and D Warrants will also be issued. The closing of the transaction is anticipated to occur on December 5, 2025.
Read more →MDCX▲ +6.8%on this newsshared move
MEDICUS PHARMA LTD. ENTERS INTO $5.1 MILLION WARRANT INDUCEMENT Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction Philadelphia, PA
Medicus Pharma Ltd. has entered into a warrant inducement agreement to exercise Series A and Series B Warrants, which is projected to generate approximately $5.1 million. The exercise price for the warrants has been reduced to $1.92, and the company will issue new Series C and D Warrants to the investor at a price of $2.00 per share. Maxim Group LLC is acting as the exclusive financial advisor for this transaction, which is expected to close on or about December 5, 2025. This action reflects Medicus Pharma's ongoing efforts to secure funding for its ambitious clinical development programs.
Read more →MDCX▼ -10.2%on this news
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer while she continues as President. This decision aims to ensure leadership continuity following the resignation of Jim Quinlan. The company is advancing its clinical development programs, including promising results from its SKNJCT-003 study for basal cell carcinoma. Additionally, regulatory approvals in the UK support the expansion of its clinical studies.
Read more →MDCX▼ -10.2%on this newsshared move
Filed by newsfilecorp.com MEDICUS PHARMA LTD. APPOINTS CAROLYN BONNER AS CHIEF FINANCIAL OFFICER IN ADDITION TO HER ROLE AS PRESIDENT Carolyn Bonner succeeds James ("Jim") Quinlan who has resigned for health reasons afte
Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer, additionally retaining her role as President. Bonner steps in following the resignation of former CFO Jim Quinlan, who left for health reasons after a medical leave. Her leadership is expected to enhance operational and financial integration as the company progresses in its clinical development programs. The organization is currently involved in several significant clinical initiatives, including ongoing studies for its novel therapies aimed at treating basal cell carcinoma and expanding its portfolio through recent acquisitions.
Read more →MDCX▼ -7%on this news
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
Medicus Pharma Ltd. is advancing novel treatment innovations for prostate and skin cancers. They are developing next-generation hormone deprivation therapies aimed at reducing cardiovascular risks associated with conventional treatments. Additionally, the company has introduced a dissolvable microneedle patch for skin cancer treatment that aims to provide a less invasive option compared to Mohs surgery. Recent regulatory approvals in the UK further support the expansion of their clinical studies, reflecting ongoing progress in their therapeutic research.
Read more →MDCXMedicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. has filed an FDA Commissioner’s National Priority Voucher application for its investigational drug Skinject (SKNJCT-003), a non-invasive treatment for basal cell carcinoma (BCC). This submission highlights the drug's alignment with national health priorities, aiming to improve access and affordability for patients, particularly those with Gorlin syndrome. The company is currently conducting a Phase 2 clinical study to evaluate the drug's effectiveness.
Read more →MDCXMedicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. announced the submission of an FDA CNPV application for SkinJect (SKNJCT-003), a novel microneedle treatment for basal cell carcinoma. The application aligns with the FDA's national health priorities, potentially allowing for expedited review and approval. Early clinical results indicate more than 60% lesion clearance, and the therapy aims to improve access to cancer treatment, especially for patients with Gorlin syndrome. The company also secured approvals in the UK to expand its clinical study for this innovative treatment.
Read more →MDCXMedicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Medicus Pharma Ltd. reported significant advancements in its clinical development programs and financial results for Q3 2025. The company is progressing with its Skinject clinical trials and has received positive feedback from the FDA. Additionally, Medicus completed the acquisition of Antev, enhancing its pipeline with Teverelix, a new treatment for prostate cancer. The company also announced a collaboration with the Gorlin Syndrome Alliance to improve patient access to its therapies.
Read more →MDCXFiled by newsfilecorp.com MEDICUS PHARMA LTD. PROVIDES CORPORATE UPDATES AND REPORTS THIRD QUARTER 2025 FINANCIAL HIGHLIGHTS Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Tevereli
Medicus Pharma Ltd. reported its third quarter 2025 financial highlights, showcasing progress in clinical development programs, including doxorubicin-containing microneedle arrays and the acquisition of Antev, which could enhance its treatment offerings for prostate cancer. The company received favorable feedback from the FDA, supporting its development pathway for Skinject and expanded its studies to regions including the UK and UAE. However, the company also noted a substantial increase in operational expenses and a significant net loss compared to the previous year, raising questions about its financial sustainability.
Read more →MDCX▼ -5.4%on this newsshared move
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. has secured full regulatory and ethical approvals in the UK to expand its Phase 2 clinical study (SKNJCT-003) for the non-invasive treatment of basal cell carcinoma (BCC) using Doxorubicin Microneedle Array (D-MNA). This expansion aims to enhance patient recruitment and clinical data collection for a pivotal study program. The study is currently active in the US and will now include additional sites in the UK.
Read more →MDCXMedicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject™ in Patients with Gorlin Syndrome
Medicus Pharma Ltd. has announced a collaboration with the Gorlin Syndrome Alliance to pursue compassionate use of SKINJECT™, an investigational therapy for patients with Gorlin Syndrome. This partnership aims to facilitate access to SKINJECT™ for patients with recurrent or inoperable basal cell carcinomas through the FDA's Expanded Access IND Program. The initiative will also gather real-world safety and tolerability data to support future regulatory efforts.
Read more →MDCXMedicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Medicus Pharma Ltd. has announced a collaboration with the Gorlin Syndrome Alliance to pursue a compassionate use pathway for its investigational therapy, SKINJECT™, in patients affected by Gorlin Syndrome. This partnership aims to facilitate expanded access to the treatment for patients with recurrent or inoperable basal cell carcinomas (BCCs) while gathering real-world safety and data insights. The ongoing Phase 2 clinical study for SKINJECT™ is reported to show promising interim results, indicating a potential new option for managing this rare genetic condition characterized by multiple skin cancers.
Read more →MDCXMedicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. has announced the enrollment of the first patient in its Phase 2 clinical study SKNJCT-004 in the UAE, aimed at non-invasively treating basal cell carcinoma (BCC) of the skin. The study will involve 36 participants across six sites, including Cleveland Clinic Abu Dhabi. This milestone expands Medicus's clinical efforts beyond the U.S. and highlights the global challenge of BCC.
Read more →MDCX▼ -6.5%on this news
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
Medicus Pharma Ltd. will present at the Maxim Growth Summit on October 22-23, 2025, in New York City. CEO Dr. Raza Bokhari will discuss the company's clinical development programs for its therapeutic assets, Skinject and Teverelix, which have significant market potential. The company is also expanding its clinical trials and received positive FDA feedback regarding its development plans.
Read more →MDCXMedicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
Medicus Pharma Ltd. will present at the Family Office Summit in Dubai on October 9, 2025. CEO Dr. Raza Bokhari will discuss innovation in biotech and AI's role in drug development. The company is conducting a Phase 2 study for SKNJCT-003, showing promising interim results. Medicus has also expanded its clinical studies and acquired Antev, enhancing its therapeutic offerings.
Read more →MDCXMedicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
Medicus Pharma Ltd. received positive feedback from the FDA during a Type C meeting regarding its Skinject product, which utilizes dissolvable Doxorubicin microneedle arrays to treat basal cell carcinoma. The FDA endorsed the 505(b)(2) regulatory pathway, indicating that a relative bioavailability study could support the clinical bridge for the product. The company aims to complete patient recruitment for its ongoing Phase 2 study by the end of 2025 and plans to request an End-of-Phase 2 meeting in early 2026.
Read more →MDCX▼ -8.9%on this newsshared move
Medicus Pharma Ltd. To Present at Brookline Capital Markets
Medicus Pharma Ltd. will present updates on its Doxorubicin Microneedle Array treatment for basal cell carcinoma and Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer. The fireside chat, scheduled for September 29, 2025, will feature key executives discussing the progress of their clinical studies, including promising interim results from ongoing trials.
Read more →MDCXMedicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
Medicus Pharma Ltd. has announced a successful $8 million non-dilutive debenture financing to expedite the development of Teverelix, a novel GnRH antagonist targeting Acute Urinary Retention and high cardiovascular risk prostate cancer. The financing is expected to enhance the company's clinical programs and capitalize on a substantial market opportunity. The debenture carries an 8% interest rate and includes specific covenants and conditions.
Read more →MDCXMEDICUS PHARMA LTD. ANNOUNCES $8.0 MILLION NON-DILUTIVE DEBENTURE FINANCING The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market
Medicus Pharma Ltd. has announced an $8 million non-dilutive debenture financing agreement with YA II PL, Ltd. to accelerate the development of Teverelix, a new GnRH antagonist intended for treating Acute Urinary Retention and high cardiovascular risk in prostate cancer. The financing is part of the company's strategy to leverage its market opportunities estimated at $6 billion. The debenture has a one-year maturity and includes provisions for redemption and potential increases in interest rates in the event of default. This step reinforces Medicus's commitment to advancing its innovative therapeutics in the oncology sector.
Read more →MDCX▲ +11.2%on this news
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. has initiated patient recruitment for its SKNJCT-004 Phase 2 clinical study at Cleveland Clinic Abu Dhabi, targeting non-invasive treatment for basal cell carcinoma (BCC). The study will enroll 36 participants across multiple UAE sites and follows the earlier approval from the UAE Department of Health. The company is also advancing its SKNJCT-003 study in the U.S., which has shown promising interim results.
Read more →MDCX▲ +7.2%on this news
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Medicus Pharma Ltd. has successfully acquired 98.6% of Antev Limited for approximately $2.97 million in cash and shares. Antev is developing Teverelix, a next-generation GnRH antagonist targeting acute urinary retention and high cardiovascular risk prostate cancer, representing a market opportunity of around $6 billion. The acquisition is expected to enhance Medicus's clinical development capabilities.
Read more →MDCX▲ +7.2%on this newsshared move
MEDICUS PHARMA LTD. COMPLETES ACQUISITION OF ANTEV LIMITED Antev is developing Teverelix , a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostat
Medicus Pharma Ltd. has successfully acquired 98.6% of Antev Limited for approximately US$2.97 million in cash and shares. Antev is focused on developing Teverelix, a next generation GnRH antagonist targeting acute urinary retention and advanced prostate cancer in patients with high cardiovascular risk. The acquisition aims to bolster Medicus's therapeutic offerings and enhance its strategic depth in drug development, with Teverelix representing a notable market potential of about US$6 billion. Key appointments to Medicus's board following the acquisition are also expected to strengthen the company’s management structure.
Read more →MDCX▲ +20.1%on this news
MEDICUS PHARMA LTD. PROVIDES UPDATE ON DOXORUBICIN CONTAINING NOVEL MICRONEEDLE ARRAY (D-MNA) CLINICAL DEVELOPMENT PROGRAM FOR THE TREATMENT OF BASAL CELL CARCINOMA (BCC) OF THE SKIN AND REPORTS SECOND QUARTER 2025 FINAN
Medicus Pharma Ltd. has provided an update on its Doxorubicin-containing microneedle array (D-MNA) clinical development program for treating basal cell carcinoma (BCC). The FDA has accepted the company's Type C meeting request, and over 75% of patients have already been randomized in the ongoing Phase 2 study. Furthermore, recent financial highlights demonstrate a significant net loss; however, the company has strengthened its balance sheet with substantial funding and continues to pursue its clinical development agenda amid rising operating costs.
Read more →MDCX▼ -7.4%on this news
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
Medicus Pharma Ltd. has entered a memorandum of understanding with Helix Nanotechnologies to develop thermostable infectious disease vaccines. The collaboration will combine HelixNano's mRNA vaccine platform with Medicus's microneedle array delivery technology. The parties aim to form a joint venture for co-development and commercialization, with initial research activities underway. The project includes a Phase 1 clinical study comparing delivery methods for HelixNano's vaccine candidate HN-0001.
Read more →MDCX▼ -7.4%on this newsshared move
Filed by newsfilecorp.com MEDICUS PHARMA LTD. ANNOUNCES A MEMORANDUM OF UNDERSTANDING (MOU) WITH HELIX NANOTECHNOLOGIES INC. TO DEVELOP THERMOSTABLE INFECTIOUS DISEASE VACCINES The MOU intends to combine proprietary mRNA
Medicus Pharma Ltd. has announced a memorandum of understanding with Helix Nanotechnologies Inc. to collaborate on the development of thermostable infectious disease vaccines. The MoU signifies both companies' intention to merge their proprietary technologies: HelixNano's mRNA vaccine platform and Medicus' microneedle array delivery method. They plan to engage in good faith negotiations toward forming a joint venture for the co-development and commercialization of mRNA-based vaccines. Preliminary collaborative activities include the production of clinical-grade mRNA vaccine-loaded microneedles for a Phase 1 clinical study.
Read more →MDCXFiled by newsfilecorp.com MEDICUS PHARMA LTD. ANNOUNCES VOTING RESULTS FOLLOWING THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Dir
Medicus Pharma Ltd. held its annual and special meeting of shareholders on July 22, 2025, where all proposed resolutions were passed, including the election of eight board members. Notably, Congresswoman Cathy McMorris Rodgers and Ajay Raju, Esq. have joined the board, contributing significant experience and leadership to the company. Dr. Raza Bokhari, the Executive Chairman, emphasized the board's balanced and diverse composition, which positions Medicus for effective governance and strategic growth in drug development.
Read more →MDCX▼ -12.1%on this news
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
Medicus Pharma Ltd. has submitted a Type C meeting request to the FDA to discuss the development of its Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA) for treating Basal Cell Carcinoma. The meeting aims to align on the clinical pathway and seek feedback on dosing, study design, and safety assessments. The company is currently conducting a Phase 2 clinical study, SKNJCT-003, which has shown promising interim results.
Read more →MDCXMedicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Antev shareholders will receive approximately 17% equity in Medicus and up to $65 million in contingent payments tied to FDA approvals. The transaction is expected to close by the end of August 2025, pending certain conditions.
Read more →MDCXMEDICUS PHARMA LTD ANNOUNCES A DEFINITIVE AGREEMENT TO ACQUIRE ANTEV LTD. UK Antev Shareholders to Receive Aggregate 17% Equity Stake in Medicus plus US$65 Million in Contingent Payments Philadelphia, Pennsylvania
Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage biotech company. Under the terms of the agreement, Antev shareholders will receive a 17% equity stake in Medicus and contingent payments of up to US$65 million based on regulatory approvals. The acquisition aims to enhance Medicus's drug development portfolio with Antev's flagship product, Teverelix, designed for prostate cancer and acute urinary retention indications. The transaction is expected to close by August 2025, pending shareholder and regulatory approvals.
Read more →MDCX▼ -6%on this news· ran to +24% by day 3
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Medicus Pharma Ltd. has appointed Andrew Smith as Chief Operating Officer, bringing over 30 years of experience in asset management. The company is advancing its SKNJCT-003 Phase 2 clinical study for basal cell carcinoma, with over 50 patients randomized and a positive interim analysis showing more than 60% clinical clearance. Additionally, Medicus is expanding its clinical trials into Europe and the UAE.
Read more →MDCX▼ -6%on this news· ran to +24% by day 3shared move
Filed by newsfilecorp.com MEDICUS PHARMA LTD. ANNOUNCES APPOINTMENT OF ANDREW SMITH AS CHIEF OPERATING OFFICER PROVIDES UPDATE ON SKNJCT-003 PHASE 2 CLINICAL STUDY FOR THE TREATMENT OF BASAL CELL CARCINOMA (BCC) USING NO
Medicus Pharma Ltd. announces the appointment of Andrew Smith as Chief Operating Officer, leveraging his extensive experience in asset management and financial operations. The company also updates on its phase 2 clinical study, SKNJCT-003, for treating basal cell carcinoma, reporting a positive interim analysis with over 60% clinical clearance and randomization of more than 50 of the targeted 90 patients. Additionally, Medicus is expanding clinical trial efforts in Europe and the UAE, while pursuing the acquisition of Antev, a biopharma company focused on developing new therapies for prostate cancer.
Read more →MDCXMedicus Pharma Ltd. to Present at 2025 Bio International Convention
Medicus Pharma Ltd. will present at the 2025 Bio International Convention, providing updates on its clinical trials and corporate developments. The company is conducting a Phase 2 study for its non-invasive treatment for basal cell carcinoma, showing promising interim results. Additionally, Medicus is expanding its clinical trials into Europe and the UAE, while pursuing an acquisition of Antev Ltd.
Read more →MDCXMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Medicus Pharma Ltd. has submitted a product development plan to the FDA to treat external squamous cell carcinoma (SCC) in horses using a novel Doxorubicin-containing microneedle array patch. The company aims to secure concurrence under the Minor Use in Major Species designation, which could grant them exclusive marketing rights for seven years. This innovative approach addresses a significant market opportunity in veterinary oncology.
Read more →MDCXMedicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
Medicus Pharma Ltd. has successfully closed a public offering, raising $7 million by selling 2,260,000 units at $3.10 each. The funds will primarily be used to support a Phase 2 clinical trial for a novel treatment for basal cell carcinoma. The company may also expand its trials to cover additional skin diseases.
Read more →MDCX▼ -29.8%on this newsshared move
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Medicus Pharma Ltd. has announced the pricing of its public offering, raising $7.0 million through the sale of 2,260,000 units at $3.10 each. The proceeds will primarily fund a Phase 2 clinical trial for a novel treatment for basal cell carcinoma. The offering is expected to close on June 2, 2025, pending customary conditions.
Read more →MDCX▼ -11.8%on this news· ran to -39% by day 3shared move
MEDICUS PHARMA LTD. ANNOUNCES PRICING OF $7.0 MILLION PUBLIC OFFERING Philadelphia, PA
Medicus Pharma Ltd. has announced the pricing of a public offering at $7.0 million, set to close on June 2, 2025. The offering consists of 2,260,000 units priced at $3.10, which will fund a Phase 2 clinical trial for a treatment aimed at basal cell carcinoma. The company also plans to use the proceeds to potentially expand its clinical trials to address other non-melanoma skin diseases.
Read more →MDCX▼ -8.2%on this news· ran to -47% by day 3
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. has received approval from the UAE Department of Health to initiate its Phase 2 clinical study (SKNJCT-004) targeting basal cell carcinoma. The study will randomize 36 participants across four clinical sites in the UAE, including Cleveland Clinic Abu Dhabi. This follows a successful Phase 1 study that demonstrated the safety and tolerability of the investigational product D-MNA.
Read more →MDCXMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Medicus Pharma Ltd. has announced a binding letter of intent to acquire Antev Ltd. for approximately $75 million in a share exchange transaction. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at treating acute urinary retention and advanced prostate cancer. The transaction is expected to close by June 2025, pending regulatory approvals and satisfactory due diligence.
Read more →MDCXFiled by newsfilecorp.com MEDICUS PHARMA LTD ANNOUNCES A BINDING LETTER OF INTENT TO ACQUIRE ANTEV LTD. FOR US $75 Million IN A SHARE EXCHANGE TRANSACTION Antev Shareholders to Receive Aggregate 19% Equity Stake in Medic
Medicus Pharma Ltd. has announced a binding letter of intent to acquire Antev Ltd. for $75 million in a share exchange transaction. Antev shareholders will receive a 19% equity stake in Medicus along with potential contingent payments of $65 million based on future FDA approvals. Antev's Teverelix, a next-generation GnRH antagonist, aims to target acute urinary retention and advanced prostate cancer in high cardiovascular risk patients. The deal is expected to close by June 2025, pending regulatory and corporate approvals, although successful negotiations are not guaranteed.
Read more →MDCXFiled by newsfilecorp.com
Medicus Pharma Ltd. has announced the cancellation of its upcoming Annual General Special Meeting originally scheduled for May 22, 2025. The meeting's record date for voting was set for April 22, 2025. Additionally, the Issuer will not send proxy materials directly to beneficial holders, further limiting communication on the matter.
Read more →MDCX▼ -23.2%on this news
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Medicus Pharma Ltd. has successfully closed a $4.2 million Regulation A offering, selling 1,490,000 units at $2.80 each. The proceeds will primarily fund a Phase 2 clinical trial for a novel treatment of basal cell carcinoma. The company may also expand its trials to include other non-melanoma skin diseases.
Read more →MDCXMedicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Medicus Pharma Ltd. has announced the pricing of its $4.2 million Regulation A offering, consisting of 1,490,000 units priced at $2.80 each. The proceeds will primarily fund a Phase 2 clinical trial for a novel treatment for basal cell carcinoma. The offering is set to close on March 10, 2025, pending customary conditions.
Read more →MDCXMedicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. announced a positive interim analysis for its SKNJCT-003 Phase 2 clinical study aimed at treating basal cell carcinoma non-invasively. The study, involving 60 patients across nine sites in the U.S., reported over 60% of subjects achieving complete clinical clearance. The investigational product, D-MNA, showed good tolerance without serious adverse events. The company intends to submit findings to the FDA to discuss the clinical pathway.
Read more →MDCXMEDICUS PHARMA LTD. ANNOUNCES PRICING OF $4.2 MILLION REGULATION A OFFERING Philadelphia, PA
Medicus Pharma Ltd. has announced the pricing of its Regulation A offering, amounting to $4.2 million for 1,490,000 units priced at $2.80 each. The proceeds will primarily be allocated to a Phase 2 proof of concept clinical trial for a novel treatment for basal cell carcinoma, alongside potential expansions into other skin diseases. The offering is expected to close on March 10, 2025, pending customary conditions. This move indicates the company's commitment to advancing its innovative therapeutic strategies in oncology.
Read more →MDCX▲ +12.2%on this news· ran to -28% by day 3
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Medicus Pharma Ltd. has announced the submission of a Phase 2 clinical design (SKNJCT-004) to the UAE Department of Health to non-invasively treat basal cell carcinoma (BCC) of the skin. The study will involve 36 patients across four sites in the UAE and will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. The company aims to expand its clinical development program and gather important data on its novel treatment.
Read more →MDCX▲ +19.5%on this news· ran to +31% by day 3
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Medicus Pharma has updated on its Phase 2 clinical study SKNJCT-003 for treating nodular basal cell carcinoma, reporting that over 50% of the 60 patients have been randomized. The company plans to complete an interim data analysis by the end of Q1 2025 and aims to discuss the clinical pathway with the FDA in a Type C meeting in Q2 2025. The study evaluates the efficacy of two doses of D-MNA compared to a placebo.
Read more →MDCXMedicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Medicus Pharma Ltd. has entered into a Standby Equity Purchase Agreement allowing it to sell up to $15 million in shares. The company also announced its intention to voluntarily delist from the TSX Venture Exchange, focusing on its Nasdaq listing, which represents the majority of its trading volume. This strategic move aims to enhance its capital markets strategy while continuing its clinical development programs.
Read more →MDCXFiled by newsfilecorp.com MEDICUS PHARMA LTD. ENTERS INTO STANDBY EQUITY PURCHASE AGREEMENT AND ANNOUNCES INTENTION TO VOLUNTARILY DELIST FROM THE TSX VENTURE EXCHANGE (TSXV) Medicus Pharma Ltd.'s shares will remain list
Medicus Pharma Ltd. announced a Standby Equity Purchase Agreement allowing it to sell up to $15 million in shares to an investor. Concurrently, the company plans to voluntarily delist its shares from the TSX Venture Exchange, citing low trading volumes as a key reason. Despite the delisting, Medicus will continue to be listed on NASDAQ, where the majority of its trading volume occurs. The delisting is subject to conditions and approvals from the TSXV. The company maintains that it remains committed to transparency in its operations, continuing to report as a "reporting issuer" in Canada.
Read more →MDCX▲ +6.1%on this news· ran to +20% by day 3
NOTICE OF CHANGE OF AUDITOR TO: EisnerAmper LLP MNP LLP AND TO: Ontario Securities Commission Alberta Securities Commission British Columbia Securities Commission The Manitoba Securities Commission Financial and Consumer
Medicus Pharma Ltd. has announced a change of auditor from MNP LLP to EisnerAmper LLP, effective December 19, 2024. The transition was initiated by the former auditor and has received approval from both the audit committee and the board of directors. Importantly, there were no reservations or modified opinions in the former auditor's reports, and no reportable events were noted. This action aligns with regulatory compliance as per the National Instrument 51-102.
Read more →MDCXMedicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Medicus Pharma Ltd. has received Minor Use in Major Species (MUMS) designation from the FDA for its Doxorubicin-containing microneedle array (D-MNA) patch aimed at treating external squamous cell carcinoma in horses. This designation provides a seven-year exclusive marketing period post-approval. The company anticipates launching a commercially viable product as early as 2026, highlighting the treatment's innovative, non-invasive approach.
Read more →MDCXMEDICUS PHARMA LTD. ANNOUNCES MINOR USE (MUMS) DESIGNATION FROM THE FDA FOR DOXORUBICIN-CONTAINING MICRONEEDLE ARRAY(D-MNA) PATCH COMPANY TO SUBMIT PRODUCT DEVELOPMENT PLAN TO TREAT EXTERNAL SQUAMOUS CELL CARCINOMA (SCC)
Medicus Pharma Ltd. announced that its Doxorubicin-containing microneedle array patch received Minor Use in Major Species Designation (MUMS) from the FDA. The MUMS designation allows Medicus to pursue an extended period of exclusive marketing for its novel patch intended to treat external squamous cell carcinoma (SCC) in horses. The company aims to submit a product development plan, looking to capitalize on a market opportunity in equine oncology. The patch is designed to deliver doxorubicin to target tumors non-invasively, representing a significant advancement in treatment options for horses.
Read more →MDCX▼ -8.7%on this news
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Medicus Pharma Ltd. has announced a collaboration with Swanielle Inc. to expand its Phase 2 clinical study for Basal Cell Carcinoma treatment in the Asia Pacific region. The ongoing study in the U.S. has already randomized over 25% of its target enrollment. Medicus plans to conduct an interim data analysis and engage with the FDA regarding the clinical pathway in 2025.
Read more →MDCX▼ -8.7%on this newsshared move
MEDICUS PHARMA LTD. ANNOUNCES COLLABORATION AGREEMENT TO EXPAND PHASE 2 CLINICAL STUDY IN ASIA PACIFIC REGION PROVIDES UPDATE ON SKNJCT-003 PHASE 2 CLINICAL STUDY FOR TREATMENT OF NODULAR BASAL CELL CARCINOMA (BCC) CURRE
Medicus Pharma Ltd. has announced a collaboration agreement with Swanielle Inc. to expand its Phase 2 clinical study of Basal Cell Carcinoma (BCC) to the Asia-Pacific region. The ongoing clinical study, SKNJCT-003, is currently underway in the United States, with more than 25% of the expected 60 patients already enrolled. Medicus plans an interim data analysis in early 2025, aiming to seek alignment with the FDA on further development of the treatment. The study indicates promising safety and efficacy results from the investigational drug, D-MNA.
Read more →MDCX▲ +7.8%on this news· ran to +40% by day 3
MANAGEMENT'S DISCUSSION AND ANALYSIS The following management's discussion and analysis ("MD&A") of results of operations and financial conditions of Medicus Pharma Ltd. ("Medicus", the "Company", "we", "our", "us" and s
Medicus Pharma Ltd. reported on its operational and financial conditions as of September 30, 2024, along with forward-looking statements regarding its clinical and business strategies. The company is developing a novel microneedle array system for treating skin cancers and has had some success in preliminary trials. However, challenges arose when the SKNJCT-002 trial was paused, and the FDA required additional information for the upcoming clinical study SKNJCT-003. The MD&A emphasizes Medicus's commitment to addressing unmet medical needs and advancing drug development.
Read more →MDCX▼ -6.7%on this news
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Medicus Pharma Ltd. has appointed Dr. Faisal Mehmud as Chief Medical Officer, leveraging his extensive experience in clinical development and medical affairs across multiple therapeutic areas. This strategic move aims to enhance the company's drug development pipeline, particularly focusing on their novel non-invasive dissolvable microneedle array treatment for basal cell carcinoma. Additionally, Dr. Edward J. Brennan has been promoted to Chief Scientific Officer, bolstering the executive team as they advance the D-MNA phase 2 study. The leadership transition is expected to drive collaboration with strategic partners and optimize patient outcomes.
Read more →MDCX▼ -6.7%on this newsshared move
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Medicus Pharma Ltd. has successfully closed its initial public offering in the U.S., raising $4.0 million through the sale of 970,000 units. The proceeds will primarily fund a Phase 2 clinical trial for treating basal cell carcinoma using a novel dissolvable microneedle patch. Trading for the common shares and warrants has commenced on Nasdaq.
Read more →MDCXMedicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Medicus Pharma Ltd. has announced the pricing of its initial public offering in the U.S., raising US$4.0 million by offering 970,000 units at US$4.125 each. The funds will be used to finance a Phase 2 clinical trial for a novel treatment for basal cell carcinoma. Trading is set to begin on Nasdaq on November 14, 2024, with the offering expected to close on November 15, 2024.
Read more →MDCXMEDICUS PHARMA LTD. ANNOUNCES PRICING OF US$4.0M INITIAL PUBLIC OFFERING IN THE UNITED STATES Toronto, Ontario & Philadelphia, PA
Medicus Pharma Ltd. has priced its initial public offering in the United States at $4.0 million, with units priced at $4.125 each. The offering, consisting of common shares and warrants, will begin trading on Nasdaq on November 14, 2024. The funds raised are intended to finance a Phase 2 clinical trial for treating basal cell carcinoma, along with potential expansions to other skin disease trials. The offering is expected to close on November 15, 2024, subject to standard closing conditions.
Read more →MDCXMedicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing
Medicus Pharma Ltd. has completed a 2-to-1 share consolidation in preparation for its proposed U.S. initial public offering. The consolidation reduces the number of outstanding shares from approximately 21.7 million to about 10.8 million. The company anticipates trading on a consolidated basis on the TSX Venture Exchange starting October 28, 2024.
Read more →MDCXMedicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults
Medicus Pharma Ltd. has announced the enrollment of the first patient in its Phase 2 trial, SKNJCT-003, aimed at treating nodular basal cell carcinoma (nBCC). The trial will involve up to 60 patients across six sites in the U.S. and will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Previous trials indicated that D-MNA was well-tolerated with promising results.
Read more →MDCXMedicus Pharma Ltd. Submits Updated Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. has submitted an updated Phase 2 clinical protocol to the FDA for a non-invasive treatment of basal cell carcinoma using doxorubicin micro-needle arrays. The submission includes comprehensive safety data and updates to the clinical protocol. The study aims to evaluate the efficacy of two dose levels in a randomized, double-blinded, placebo-controlled design. The incorporation of AI and confocal microscopy is intended to enhance assessment accuracy.
Read more →MDCXMedicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Medicus Pharma Ltd. has successfully closed a non-brokered private placement, raising approximately $5.85 million through the issuance of 2,922,500 common shares. Additionally, all outstanding convertible notes have been converted into shares, further enhancing the company's equity. The funds will support ongoing research and development initiatives.
Read more →MDCXMedicus Pharma Ltd. Announces Proposed Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Medicus Pharma Ltd. has announced a non-brokered private placement of 2,922,500 common shares at $2.00 each, aiming to raise approximately $5.84 million. The offering is set to close around June 28, 2024, pending regulatory approval. Additionally, holders of convertible notes can convert their notes into shares on the same date, further strengthening the company's financial position.
Read more →MDCXMedicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
Medicus Pharma Ltd. has filed a registration statement with the SEC for a proposed initial public offering in the U.S. The offering will consist of units that include common shares and warrants, with plans to list on a national securities exchange. Specific details regarding the number of securities and pricing are yet to be finalized, pending SEC review.
Read more →MDCXMedicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes
Medicus Pharma Ltd. has successfully completed the first closing of its private placement of unsecured convertible notes, raising US$5,172,500. The company plans to issue additional notes, with a total of up to US$10 million expected. Proceeds will fund research and development and support an initial public offering in the U.S. The notes carry a 10% interest rate and have specific conversion terms.
Read more →MDCXMedicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes
Medicus Pharma Ltd. has announced a proposed private placement of unsecured convertible notes, aiming to raise approximately US$5.17 million in the first closing. The notes will bear a 10% interest rate and are convertible into common shares under specific conditions. Proceeds will support the company's R&D initiatives and working capital.
Read more →MDCXMedicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. has received favorable comments from the FDA regarding its Phase 2 clinical protocol for treating basal cell carcinoma using micro-array needles with doxorubicin. The FDA's feedback indicates agreement with the study design, although they requested additional data and an updated investigator brochure. The company plans to submit the requested information in Q2 2024.
Read more →MDCXMedicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer
Medicus Pharma Ltd. has appointed Erica Monaco as Chief Operating Officer, bringing extensive experience from her previous role as CEO at Biofrontera Inc. Monaco's leadership is expected to strengthen the company's efforts in developing a novel treatment for Basal Cell Carcinoma. Additionally, Medicus has engaged an investment bank to explore financing and US listing opportunities.
Read more →MDCXMedicus Pharma Ltd. Publishes Phase 1 Clinical Study Report Demonstrating Safety & Tolerability in All Participants with Basal Cell Carcinoma
Medicus Pharma Ltd. has published a Phase 1 clinical study report for its SKNJCT-001 trial, which assessed the safety and tolerability of a new treatment for basal cell carcinoma. The study found that the investigational product, D-MNA, was safe across all dose levels, with no significant adverse effects. Additionally, six participants experienced complete responses, indicating promising efficacy.
Read more →MDCXMedicus Pharma Ltd. Announces the Filing of a Final Base Shelf Prospectus
Medicus Pharma Ltd. has filed a final short form base shelf prospectus allowing it to offer up to US$50 million in various securities over a 25-month period. While the company aims to maintain financial flexibility, it has no immediate plans to conduct any offerings. The prospectus details will be provided in a supplement if offerings occur.
Read more →MDCXMedicus Pharma Ltd. Announces Listing on Frankfurt Stock Exchange
Medicus Pharma Ltd. has announced the listing of its common shares on the Frankfurt Stock Exchange under the ticker symbol 'N46'. The company remains listed on the TSX Venture Exchange as 'MDCX'. Medicus focuses on investing in life sciences and biotechnology companies, and its subsidiary, Skinject Inc., is currently recruiting for an FDA approved phase 2 trial.
Read more →MDCXMedicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. has submitted a Phase 2 IND clinical protocol to the FDA for a non-invasive treatment of basal cell carcinoma (BCC) using doxorubicin micro-array needles. The randomized study aims to enroll up to 60 patients and will compare two dose levels of the treatment against a placebo. The company seeks FDA feedback to finalize the protocol, building on positive Phase 1 trial results.
Read more →MDCXMedicus Pharma Opens the Market
Medicus Pharma Ltd. has officially listed on the TSX Venture Exchange, marking a significant milestone for the company. Raza Bokhari, the Executive Chairman and CEO, along with his team, participated in the market opening ceremony. Medicus Pharma is dedicated to investing in and accelerating novel life sciences and biotechnology firms.
Read more →MDCXMedicus Pharma Ltd. to Ring the Toronto Stock Exchange Opening Bell on Thursday October 26th 2023; Appoints Paul A. Marchetto, MD, FACS as Chairman of the Scientific Advisory Board
Medicus Pharma Ltd. will ring the Toronto Stock Exchange opening bell on October 26, 2023, marking a significant milestone following its recent listing. The company has appointed Dr. Paul A. Marchetto as the Chairman of its Scientific Advisory Board, bringing valuable expertise to its leadership team. The event will be webcast live, showcasing the company's commitment to advancing its pharmaceutical initiatives.
Read more →MDCXMedicus Pharma Ltd. Announces Appointment of Huma Qamar, MD as Chief Scientific Officer & Head of R&D Program
Medicus Pharma Ltd. has appointed Dr. Huma Qamar as Chief Scientific Officer and Head of R&D Program. Dr. Qamar has a strong background in clinical research and has worked with top Ivy League institutions. The company also announced the election of James P. Quinlan as Chairman of Skinject Inc., its wholly owned subsidiary, which is focused on developing treatments for skin cancer.
Read more →MDCXMedicus Pharma Ltd. Announces Commencement of Trading on TSX Venture Exchange and Appointment of Seasoned Pharma Executive Barry Fishman to the Board of Directors
Medicus Pharma Ltd. has begun trading on the TSX Venture Exchange at CDN $2.75. The company has appointed Barry Fishman, a seasoned executive, to its board of directors. Fishman brings nearly 25 years of experience in the pharmaceutical industry. Medicus aims to enhance market awareness through partnerships with financial firms.
Read more →MDCXMedicus Pharma Ltd. Announces Closing of Business Combination
Medicus Pharma Ltd. has successfully completed its business combination with SkinJect, Inc., transforming into a wholly owned subsidiary. This merger is expected to enhance Medicus's capabilities in developing innovative pharmaceutical treatments, particularly for skin cancer. The company anticipates trading on the TSX Venture Exchange under the ticker MDCX by October 11, 2023, pending approval.
Read more →MDCXInteractive Capital Partners Corporation Announces Filing of Final Non-Offering Prospectus
Interactive Capital Partners Corporation has filed a final non-offering prospectus related to its business combination with SkinJect, Inc. The transaction is expected to close around September 29, 2023, with the resulting entity to be renamed Medicus Pharma Ltd. SkinJect's innovative patch for treating basal cell carcinoma has received FDA approval for further clinical trials.
Read more →Competitive Position
How MDCX ranks across every disease it competes inCompetitive Position is a premium feature
See how MDCX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial